A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Trial details
- Registry ID
- NCT04688931
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT04688931 | URGN | Phase 3 | Terminated | 2023-03-17Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |